The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Second quarter revenue growth of 12% was driven by the continued dominance of the cystic fibrosis (CF) portfolio and accelerating contributions from newer launches CASGEVY and JOURNAVX.

Management emphasized that the bar for new CF therapies is exceptionally high, as ALYFTREK already brings approximately 75% of patients ages 12 and older into the carrier range of sweat chloride levels.

The announced acquisition of Crinetics Pharmaceuticals establishes a fifth strategic pillar in rare endocrine diseases, adding two lead assets with an estimated $5 billion peak sales potential.

The renal franchise is positioned as a primary growth driver, with povetacicept (Pove) in IgAN receiving a November 30 PDUFA date and showing potentially best-in-class efficacy in proteinuria reduction.

Type 1 diabetes strategy is shifting to prioritize the VX-017 'Type O' universal donor program, which doubles the addressable market opportunity to approximately 120,000 patients compared to the original program.

Operational focus remains on a 'high-science' specialty commercial model, leveraging existing CF infrastructure to launch upcoming renal and endocrine therapies efficiently.

Full-year 2026 revenue guidance was raised to $13.1 billion to $13.2 billion, assuming continued CF strength and at least $500 million from non-CF products.

Management expects gross margins to normalize at just under 86% as the product mix shifts toward CASGEVY, which carries higher manufacturing costs than small-molecule products.

Key clinical catalysts for the second half of 2026 include proof-of-concept data for VX-828 in CF, DM1 study results, and expanded population data for inaxaplin in AMKD.

The Crinetics acquisition is expected to close in Q3 2026, with management projecting the transaction to become accretive to non-GAAP operating income by 2029.

Updated regulatory and commercial timelines for the Type 1 diabetes portfolio are expected later this year as the company evaluates streamlining the Type O program.

JOURNAVX gross-to-net margins are currently impacted by high Patient Support Program (PSP) usage as physician education on payer restrictions catches up to rapid prescription growth.

Management flagged that foreign exchange rates provided a 170 basis point benefit in Q2 but expects this tailwind to diminish in the second half of the year.

Commercial spending is growing faster than R&D as the company builds entirely new business units for pain and renal, whereas R&D costs are being managed through internal resource redeployment.

The voluntary manufacturing pause for zimislecel has been resolved, but it resulted in a strategic pivot to accelerate the universal donor VX-017 program.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Prescription growth is currently outpacing unrestricted payer access, leading to higher-than-forecasted use of the Patient Support Program to ensure patient access.

Management expects gross-to-net to normalize in line with other branded oral medicines by the first half of 2027 as physicians learn to navigate minor quantity limits and prior authorizations.

Management believes Pove's 52% proteinuria reduction and significant impact on Gd-IgA1 antibodies will lead to superior long-term outcomes regarding time to end-stage renal disease.

The product is positioned for market leadership based on a 'trifecta' of efficacy, safety, and patient-centric once-monthly at-home dosing via auto-injector.

The time differential between the original zimislecel program and the universal Type O program (VX-017) has shortened due to the recent manufacturing pause.

Vertex is exploring a streamlined regulatory strategy that could potentially bring the Type O program to market first or very shortly after the original program.

Vertex will only advance assets into Phase II that show clear potential to beat ALYFTREK's efficacy in bringing more patients to sweat chloride levels below 30 millimoles.

Management dismissed competitors' incremental sweat chloride data, stating that the true measure of success is the proportion of patients reaching the carrier-level threshold across all genotypes.